Skip to Main Content

4,087

Views

12

CrossRef citations to date

0

Altmetric

Articles

Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab

Ioannis Tomazosa Alexion Pharmaceuticals, Inc., Boston, MA, USACorrespondence[email protected]
View further author information

,

J. Rafael Sierraa Alexion Pharmaceuticals, Inc., Boston, MA, USAView further author information

,

Karissa M. Johnstonb Broadstreet Health Economics and Outcomes Research, Vancouver, CanadaView further author information

,

Antoinette Cheungb Broadstreet Health Economics and Outcomes Research, Vancouver, CanadaView further author information

,

Robert A. Brodskyc Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USAView further author information

&

Ilene C. Weitzd Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAView further author information